In any case, screening for carriers of IL-6 gene variants with high susceptibility to transcriptional dysregulation by IL-1β should be considered for identification of individuals with high-risk for therapy-resistant colorectal cancer. This evidence concerns the gene IL1B and colorectal cancer.